Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Completed
- Conditions
- Head & Neck Cancer
- Registration Number
- NCT03157674
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This study will be focused on HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43994
Inclusion Criteria
- HNC or undefined histology (not otherwise specified [NOS]) HNC diagnosis from 01-Jan-2013 to 30-Sep-2016 using Japanese disease code
- Age 18 years or older at initial diagnosis of HNC regardless of staging
Exclusion Criteria
- Diagnosis of another malignancy on or before the initial diagnosis of HNC with the exception of non-melanoma skin cancer and metastatic cancer
- Diagnosis of HNC before 01-Jan 2013 or after 30-Sep-2016
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients receiving radiotherapy as anti-cancer treatment Approximately 45 months Proportion of patients receiving supportive care as anti-cancer treatment Approximately 45 months Proportion of patients receiving chemotherapy as anti-cancer treatment Approximately 45 months Proportion of patients receiving surgery as anti-cancer treatment Approximately 45 months Proportion of patients receiving targeted therapy as anti-cancer treatment Approximately 45 months Distribution of Treatment History in Head and Neck Cancer (HNC) patients Approximately 45 months
- Secondary Outcome Measures
Name Time Method Distribution of overall survival (OS) by age Approximately 45 months Number of withdrawals due to AEs Approximately 45 months Distribution of overall survival (OS) by gender Approximately 45 months Distribution of overall survival (OS) by stage Approximately 45 months Distribution of overall survival (OS) by tumor site Approximately 45 months Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC At Baseline Number of treatment-limiting adverse events (AEs) Approximately 45 months Incidence of important treatment-limiting adverse events (AEs) associated with systemic therapies
Distribution of overall survival (OS) by treatment regimen Approximately 45 months
Trial Locations
- Locations (1)
Local Institution
🇯🇵Tokyo, Shibuya-ku, Japan
Local Institution🇯🇵Tokyo, Shibuya-ku, Japan